Skip to content
2000
Volume 21, Issue 8
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Glioma predominantly targets glial cells in the brain and spinal cord. There are grade I, II, III, and IV gliomas with anaplastic astrocytoma and glioblastoma multiforme as the most severe forms of the disease. Current diagnostic methods are limited in their data acquisition and interpretation, markedly affecting treatment modalities, and patient outcomes. Circulating extracellular vesicles (EVs) or “magic bullets” contain bioactive signature molecules such as DNA, RNA, proteins, lipids, and metabolites. These secretory “smart probes” participate in myriad cellular activities, including glioma progression. EVs are released by all cell populations and may serve as novel diagnostic biomarkers and efficient nano-vehicles in the targeted delivery of encapsulated therapeutics. The present review describes the potential of EV-based biomarkers for glioma management.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026620666201207100139
2021-03-01
2025-06-22
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026620666201207100139
Loading

  • Article Type:
    Review Article
Keyword(s): Biomarker; Diagnostic; Extracellular vesicle; Glioma; Smart probes; Therapeutic
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test